The oral fluoropyrimidines in cancer chemotherapy

EB Lamont, RL Schilsky - Clinical cancer research, 1999 - AACR
Clinical cancer research, 1999AACR
A classic example of a rationally developed class of anticancer drugs, the fluoropyrimidines
are now the focus of further rational approaches to cancer chemotherapy as they are
transformed into oral formulations. Given alone, oral 5-fluorouracil (5-FU) has erratic
absorption and nonlinear pharmacokinetics. However, when oral 5-FU is given as a prodrug
and/or paired with a dihydropyrimidine dehydrogenase inhibitor, the resultant 5-FU has
linear pharmacokinetics that may approximate the less myelosuppressive continuous iv …
Abstract
A classic example of a rationally developed class of anticancer drugs, the fluoropyrimidines are now the focus of further rational approaches to cancer chemotherapy as they are transformed into oral formulations. Given alone, oral 5-fluorouracil (5-FU) has erratic absorption and nonlinear pharmacokinetics. However, when oral 5-FU is given as a prodrug and/or paired with a dihydropyrimidine dehydrogenase inhibitor, the resultant 5-FU has linear pharmacokinetics that may approximate the less myelosuppressive continuous i.v. infusion schedule of 5-FU administration without the use of infusion catheters and pumps. We review the preclinical and clinical experience of several of the oral fluoropyrimidines.
AACR